Najoua Lalaoui lab

The Najoua Lalaoui lab studies the causes and consequences of inflammatory cell death programs to improve cancer treatment

Cell death programs are crucial processes in development, tissue homeostasis and immunity. ‘Too much’ cell death can lead to neurodegenerative and immune diseases and ‘too little’ cell death causes cancer. Consequently, the re-activation of cell death within tumours is one of the major goals of cancer therapies. Until recently, it was thought that the unique purpose of programmed cell death was to kill cells. However, it has become clear that dying cells release a variety of signals which communicate with the microenvironment and the immune system. Thus, how the body responds to dying cells can influence cancer progression and cancer treatments. The Najoua Lalaoui laboratory uses a range of cellular, and molecular techniques and in vivo models to investigate the causes and consequences of cell death programs regulated by the RIP kinases 1 and 3 (RIPK1/3). We apply this fundamental knowledge to design new therapeutic strategies for cancer and inflammatory diseases and to understand the impact of inflammatory cell death in cancer immunity and cancer progression.

Current projects

Related pages

NHMRC Grants Awarded to Six Peter Mac Researchers

Related links

Najoua Lalaoui PubMed

Najoua Lalaoui Twitter


Go back to the Organogenesis and Cancer Program page